Video Summary - Tim Spector: I was wrong about vitamin D! Here’s what changed

Key takeaways on vitamin D (and what changed)

Vitamin D isn’t a universal “cure.” Early enthusiasm came from studies suggesting broad benefits, but later evidence showed it’s “rubbish” for most of the conditions it was promoted for.
Potential benefits exist, but not in the way people assumed:
- Multiple sclerosis: Vitamin D can be useful for reducing risk/harm (described as reducing by “a few hours” during viral infection—context is unclear, but the takeaway is that benefits may appear in some settings).
- Type 2 diabetes: Newer studies suggest vitamin D may reduce risk of developing type 2 diabetes.
Wrong-but-understandable shift: The presenter’s view is that he was “fooled” by earlier results, and that large, well-controlled studies overturned prior assumptions.

Check your level; don’t overreact to “borderline low.”
- If your vitamin D is only borderline, it may be normal for historical levels, and many people don’t need tablets at that stage.
- Consider retesting rather than immediately supplementing.
Increase vitamin D primarily through natural sources.
- Sunlight (especially in summer): He suggests people evolved to handle fluctuating vitamin D levels, and it’s okay to be lower for part of the year.
- Food sources:
  - Oily fish: anchovies, salmon, mackerel, herring
  - Mushrooms: can produce vitamin D; the idea mentioned is to sunbathe mushrooms in a windowsill for a couple of days.
Be less fearful of the sun—avoid sunburn, but don’t overuse protection in winter.
- He cites changing expert guidance suggesting that in winter, protective creams may not be necessary and that winter sun helps meet vitamin-D-related “chemicals.”
- Protect against sunburn at other times, but in winter aim for more sunlight/daylight on skin.
Supportive mindset: He frames his approach as staying open-minded—change your mind when evidence contradicts your theory.

Base decisions on high-quality evidence (especially large placebo-controlled trials), not on:
- Small studies
- “Intermediate biomarkers” used as substitutes for real clinical outcomes

Big picture method described:
- Earlier studies relied on surrogate/intermediate biomarkers (bone turnover markers).
- Larger fracture-outcome trials with good placebo controls found no meaningful fracture reduction for most people.
- After multiple negative studies, osteoporosis experts updated practice over time.